In addition, when combined with treatments for classical abnormalities (targeted by tyrosine kinase inhibitors in CML (imatinib, dasatinib) [47,88], Notch inhibitors in T-ALL [89], and BTK inhibitors in precursor B-ALL (ibrutinib) [90]), the necessary dosage of Wnt inhibitors is expected to be lower as one can envision combination therapies targeting Wnt signaling together with the other genetic alterations to work synergistically. Here, BTK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.